BioCentury
ARTICLE | Clinical News

Agios reports Phase I safety data for IDH1/IDH2 inhibitor

May 25, 2018 3:33 PM UTC

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) reported safety data from 93 evaluable patients in a Phase I trial evaluating AG-881 to treat advanced solid tumors, including glioma, in patients with an isocitrate dehydrogenase 1 (IDH1) or IDH2 mutation. The data were released in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago.

Agios said AG-881 was associated with a "favorable" safety profile at doses of less than 100 mg. The most common adverse events reported were fatigue, nausea and dose-dependent elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. The maximum tolerated dose (MTD) has not yet been reached. The open-label, dose-escalation, U.S. trial evaluated once- and twice-daily doses of oral AG-881 in continuous 28-day cycles...